Peptide mimics of a conserved H5N1 avian influenza virus neutralization site

Biochemical Journal

Volumn 419, Issue 1, 2009, Pages 133-139

  Luo, Wenxin ^a   Chen, Yingwei ^a   Wang, Mingqiao ^a   Chen, Yixin ^a   Zheng, Zhenhua ^a   Song, Huljuan ^a   Chen, Honglin ^b   Guan, Yi ^b   Ng, Mun Hon ^a   Zhang, Jun ^a   Xia, Ningshao ^a  

^a XIAMEN UNIVERSITY   (China)

^b THE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Anti H5 monoclonal antibody; H5N1 avian influenza virus; Haemagglutination; Hepatitis virus; Influenza; Peptide mimic

Indexed keywords

ANTI-H5 MONOCLONAL ANTIBODY; H5N1 AVIAN INFLUENZA VIRUS; HAEMAGGLUTINATION; HEPATITIS VIRUS; INFLUENZA; PEPTIDE MIMIC;

ALLERGIES; AMINES; AMINO ACIDS; BINDING SITES; HYDROXYLATION; MERGERS AND ACQUISITIONS; MOLECULES; MONOCLONAL ANTIBODIES; ORGANIC ACIDS; PEPTIDES; SURFACE PLASMON RESONANCE;

VIRUSES;

CORE PROTEIN; HEMAGGLUTININ; HYBRID PROTEIN; MONOCLONAL ANTIBODY; PROTEIN P239; UNCLASSIFIED DRUG; VIRUS PROTEIN; ANTISERUM; HEPATITIS B CORE ANTIGEN; PEPTIDE; PEPTIDE LIBRARY;

AMINO ACID SEQUENCE; ANTIBODY SPECIFICITY; ANTIGEN ANTIBODY REACTION; ANTIGEN RECOGNITION; ARTICLE; BINDING COMPETITION; CONTROLLED STUDY; INFLUENZA VIRUS A H5N1; MOLECULAR MIMICRY; NONHUMAN; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN STRUCTURE; VIRAL GENETICS; VIRUS NEUTRALIZATION; VIRUS STRAIN; VIRUS VIRULENCE; ANIMAL; ARMYWORM; CELL LINE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENETICS; HEMAGGLUTINATION; HEPATITIS VIRUS; IMMUNOLOGY; METABOLISM; WESTERN BLOTTING;

AVIAN INFLUENZA VIRUS; HEPATITIS E VIRUS; MURINAE; ORTHOMYXOVIRIDAE;

ANIMALS; ANTIBODIES, MONOCLONAL; BLOTTING, WESTERN; CELL LINE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HEMAGGLUTINATION; HEPATITIS B CORE ANTIGENS; HEPATITIS VIRUSES; IMMUNE SERA; INFLUENZA A VIRUS, H5N1 SUBTYPE; PEPTIDE LIBRARY; PEPTIDES; RECOMBINANT FUSION PROTEINS; SPODOPTERA; VIRAL PROTEINS;

EID: 62749159748     PISSN: 02646021     EISSN: 14708728     Source Type: Journal    
DOI: 10.1042/BJ20080083     Document Type: Article

References (31)

1. Webster, R. G. and Hulse, D. J. (2004) Microbial adaptation and change: avian influenza. Rev. Sci. Tech. 23, 453-465
2. Reference deleted
3. Stephenson, I., Bugarini, R., Nicholson, K. G., Podda, A., Wood, J. M., Zambon, M. C. and Katz, J. M. (2005) Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. J. Infect. Dis. 191, 1210-1215
4. Stephenson, I., Gust, I., Pervikov, Y. and Kieny, M. P. (2006) Development of vaccines against influenza H5. Lancet Infect. Dis. 6, 458-460
5. Hoffmann, E., Mahmood, K., Chen, Z., Yang, C. F., Spaete, J., Greenberg, H. B., Herlocher, M. L., Jin, H. and Kemble, G. (2005) Multiple gene segments control the temperature sensitivity and attenuation phenotypes of ca B/Ann Arbor/1/66. J. Virol. 79, 11014-11021
6. Belshe, R. B., Edwards, K. M., Vesikari, T., Black, S. V., Walker, R. E., Hultquist, M., Kemble, G. and Connor, E. M. (2007) Live attenuated versus inactivated influenza vaccine in infants and young children. N. Engl. J. Med. 356, 685-696
7. Hoelscher, M. A., Garg, S., Bangari, D. S., Belser, J. A., Lu, X., Stephenson, I., Bright, R. A., Katz, J. M., Mittal, S. K. and Sambhara, S. (2006) Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice. Lancet 367, 475-481
8. Veits, J., Wiesner, D., Fuchs, W., Hoffmann, B., Granzow, H., Starick, E., Mundt, E., Schirrmeier, H., Mebatsion, T., Mettenleiter, T. C. and Romer-Oberdorfer, A. (2006) Newcastle disease virus expressing H5 HA gene protects chickens against Newcastle disease and avian influenza. Proc. Natl. Acad. Sci. U.S.A. 103, 8197-8202
9. Ge, J., Deng, G., Wen, Z., Tian, G., Wang, Y., Shi, J., Wang, X., Li, Y., Hu, S., Jiang, Y. et al. (2007) Newcastle disease virus-based live attenuated vaccine completely protects chickens and mice from lethal challenge of homologous and heterologous H5N1 avian influenza viruses. J. Virol. 81, 150-158
10. Neirynck, S., Deroo, T., Saelens, X., Vanlandschoot, P., Jou, W. M. and Fiers, W. (1999) A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat. Med. 5, 1157-1163
11. Ernst, W. A., Kim, H. J., Tumpey, T. M., Jansen, A. D., Tai, W., Cramer, D. V., Adler-Moore, J. P. and Fujii, G. (2006) Protection against H1, H5, H6 and H9 influenza A infection with liposomal matrix 2 epitope vaccines. Vaccine 24, 5158-5168
12. De Filette, M., Ramne, A., Birkett, A., Lycke, N., Lowenadler, B., Min Jou, W., Saelens, X. and Fiers, W. (2006) The universal influenza vaccine M2e-HBc administered intranasally in combination with the adjuvant CTA1-DD provides complete protection. Vaccine 24, 544-551
13. Kendal, A. P., Pereira, M. S. and Skehel, J. J. (1982) Hemagglutination inhibition. In Concepts and Procedures for Laboratory-Based Influenza Surveillance, (Kendal, A. P., Pereira, M. S. and Skehel, J. J. eds), pp. B17-B35, Centers for Disease Control and Prevention and Pan-American Health Organization, Atlanta
14. World Health Organization Global Influenza Program Surveillance Network (2005) Evolution of H5N1 avian influenza viruses in Asia. Emerg. Infect. Dis. 11, 1515-1521
15. Wu, W. L., Chen, Y., Wang, P., Song, W., Lau, S. Y., Rayner, J. M., Smith, G. J., Webster, R. G., Peiris, J. S., Lin, T. et al. (2008) Antigenic profile of avian H5N1 viruses in Asia from 2002 to 2007. J. Virol. 82, 1798-1807
16. Chen, Y., Qin, K., Wu, W. L., Li, G., Zhang, J., Du, H., Ng, M. H., Shih, J. W.-K., Guan, Y., Chen, H. and Xia, N. (2008) Broad cross protection against H5N1 avian influenza infection using monoclonal antibodies mapping to conserved viral epitopes. J. Infect. Dis. 199, 49-58
17. Purcell, A. W., McCluskey, J. and Rossjohn, J. (2007) More than one reason to rethink the use of peptides in vaccine design. Nat. Rev. Drug Discov. 6, 404-414
18. Boss, C. N., Grunebach, F., Brauer, K., Hantschel, M., Mirakaj, V., Weinschenk, T., Stevanovic, S., Rammensee, H. G. and Brossart, P. (2007) Identification and characterization of T-cell epitopes deduced from RGS5, a novel broadly expressed tumor antigen. Clin. Cancer Res. 13, 3347-3355
19. Chen, X., Scala, G., Quinto, I., Liu, W., Chun, T. W., Justement, J. S., Cohen, O. J., vanCott, T. C., Iwanicki, M., Lewis, M. G. et al. (2001) Protection of rhesus macaques against disease progression from pathogenic SHIV-89.6PD by vaccination with phage-displayed HIV-1 epitopes. Nat. Med. 7, 1225-1231
20. Khurana, S., Needham, J., Mathieson, B., Rodriguez-Chavez, I. R., Catanzaro, A. T., Bailer, R. T., Kim, J., Polonis, V., Cooper, D. A., Guerin, J. et al. (2006) Human immunodeficiency virus (HIV) vaccine trials: a novel assay for differential diagnosis of HIV infections in the face of vaccine-generated antibodies. J. Virol. 80, 2092-2099
21. Steward, M. W. (2001) The development of a mimotope-based synthetic peptide vaccine against respiratory syncytial virus. Biologicals 29, 215-219
22. Torresi, J., Stock, O. M., Fischer, A. E., Grollo, L., Drummer, H., Boo, I., Zeng, W., Earnest-Silveira, L. and Jackson, D. C. (2007) A self-adjuvanting multiepitope immunogen that induces a broadly cross-reactive antibody to hepatitis C virus. Hepatology 45, 911-920
23. Zhang, J., Gu, Y., Ge, S. X., Li, S. W., He, Z. Q., Huang, G. Y., Zhuang, H., Ng, M. H. and Xia, N. S. (2005) Analysis of hepatitis E virus neutralization sites using monoclonal antibodies directed against a virus capsid protein. Vaccine 23, 2881-2892
24. Li, S. W., Zhang, J., He, Z. Q., Gu, Y., Liu, R. S., Lin, J., Chen, Y. X., Ng, M. H. and Xia, N. S. (2005) Mutational analysis of essential interactions involved in the assembly of hepatitis E virus capsid. J. Biol. Chem. 280, 3400-3406
25. Borisova, G., Borschukova Wanst, O., Mezule, G., Skrastina, D., Petrovskis, I., Dislers, A., Pumpens, P. and Grens, E. (1996) Spatial structure and insertion capacity of immunodominant region of hepatitis B core antigen. Intervirology 39, 16-22
26. Milich, D. R., Peterson, D. L., Zheng, J., Hughes, J. L., Wirtz, R. and Schodel, F. (1995) The hepatitis nucleocapsid as a vaccine carrier moiety. Ann. N.Y. Acad. Sci. 754, 187-201
27. World Health Organization (2002) WHO Manual on Animal Influenza Diagnosis and Surveillance, 2nd edn, World Health Organization. Geneva, Switzerland, http://www.who.int/csr/resources/publications/influenza/en/ whocdscsrncs20025rev.pdf
28. Saphire, E. O., Montero, M., Menendez, A., van Houten, N. E., Irving, M. B., Pantophlet, R., Zwick, M. B., Parren, P. W., Burton, D. R., Scott, J. K. and Wilson, I. A. (2007) Structure of a high-affinity "mimotope" peptide bound to HIV-1-neutralizing antibody b12 explains its inability to elicit gp120 cross-reactive antibodies. J. Mol. Biol. 369, 696-709
29. Menendez, A., Calarese, D. A., Stanfield, R. L., Chow, K. C., Scanlan, C. N., Kunert, R., Katinger, H., Burton, D. R., Wilson, I. A. and Scott, J. K. (2008) A peptide inhibitor of HIV-1 neutralizing antibody 2G12 is not a structural mimic of the natural carbohydrate epitope on gp120. FASEB J. 22, 1380-1392
30. Dharmasena, M. N., Jewell, D. A. and Taylor, R. K. (2007) Development of peptide mimics of a protective epitope of Vibrio cholerae Ogawa O-antigen and investigation of the structural basis of peptide mimicry. J. Biol. Chem. 282, 33805-33816
31. Joyce, J. G., Krauss, I. J., Song, H. C., Opalka, D. W., Grimm, K. M., Nahas, D. D., Esser, M. T., Hrin, R., Feng, M., Dudkin, V. Y. et al. (2008) An oligosaccharide-based HIV-1 2G12 mimotope vaccine induces carbohydrate- specific antibodies that fail to neutralize HIV-1 virions. Proc. Natl. Acad. Sci. U.S.A. 105, 15684-15689